The prevalence of occult hepatitis B in chronic hepatitis C patients treated with interferon-based antiviral therapy

Basit Öğe Kaydı
dc.authoridBal, Tayibe/0000-0002-5315-122X
dc.contributor.authorBal, Tayibe
dc.contributor.authorOnlen, Yusuf
dc.date.accessioned2024-09-18T20:52:50Z
dc.date.available2024-09-18T20:52:50Z
dc.date.issued2018
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground and study aims: Occult hepatitis B infection (OBI) is known to be mostly prevalent in chronic hepatitis C (CHC) patients and OBI reactivation might be life-threatening in patients undergoing interferon (IFN)-free direct acting antiviral (DAA) therapy. As previous studies have revealed a relationship between OBI and non-response to IFN-based antiviral therapy, the aim of the current study was to determine if there was a higher prevalence of OBI in IFN non-responders than responders. Patients and Methods: This retrospective cross-sectional study was conducted in CHC patients who had previously received IFN-based antiviral therapy. Serum samples of 100 HBsAg negative CHC patients were tested for HBV DNA, anti-HBc IgG, anti-HBs, ALT and AST. The presence of OBI was compared between 50 IFN responders and 50 IFN non-responders. Patients with a history of previous HBV infection, patients with evidence of cirrhosis and patients who had received IFN therapy within the last one year were excluded from the study. Results: Anti-HBc IgG positivity was determined in 53% of the patients. HBV DNA positivity, indicating OBI was determined in 1 (1%) patient. This patient was anti-HBc IgG positive, anti-HBs negative, ALT and AST levels were normal. The HBV DNA and anti-HBc IgG positivity rates were higher in the non-responder group than in the responder group, but the difference was not statistically significant (p = 0.31 and p = 0.07 respectively). Conclusion: According to the results of this study, the prevalence of OBI is lower than expected amongst CHC patients in Turkey and it may not be necessary to apply routine screening to IFN non-responders for OBI infection before DAA therapy. However, there is a need for multicentre studies with larger patient series. (C) 2018 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.en_US
dc.description.sponsorshipScientific Research Project Committee of Mustafa Kemal University, Hatay, Turkey [12,624]en_US
dc.description.sponsorshipThis study was supported by the Scientific Research Project Committee of Mustafa Kemal University, Hatay, Turkey (Project number: 12,624).en_US
dc.identifier.doi10.1016/j.ajg.2018.02.001
dc.identifier.endpage36en_US
dc.identifier.issn1687-1979
dc.identifier.issn2090-2387
dc.identifier.issue1en_US
dc.identifier.pmid29503077en_US
dc.identifier.scopus2-s2.0-85042562178en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage33en_US
dc.identifier.urihttps://doi.org/10.1016/j.ajg.2018.02.001
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11433
dc.identifier.volume19en_US
dc.identifier.wosWOS:000427745100007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofArab Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOccult hepatitis Ben_US
dc.subjectChronic hepatitis Cen_US
dc.subjectInterferon alfaen_US
dc.subjectPegylated interferon alfaen_US
dc.subjectDirect acting antiviral therapyen_US
dc.titleThe prevalence of occult hepatitis B in chronic hepatitis C patients treated with interferon-based antiviral therapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
293.16 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu